Loss Per Share Basic News Today

-- STAR-0215 Granted Fast Track Designation by the U.S. FDA ---- New Results from Healthy Subjects Informing STAR-0215 Administration Plan Expected in Q4 2023 ---- ALPHA-STAR on Track with Initial Proof-of-Concept Results in Patients Anticipated Mid-2024 --BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:A...

-- Administration of STAR-0215 to HAE Patients is Underway in the ALPHA-STAR Phase 1b/2 Trial ---- ALPHA-STAR on Track for Initial Proof-of-Concept Results Anticipated Mid-2024 ---- Mechanistic Modeling Data Supports STAR-0215 Administration Once Every Three or Six Months for Robust Suppression of HAE Attacks --BOST...

-- Administration of STAR-0215 to HAE Patients is Underway in the ALPHA-STAR Phase 1b/2 Trial -- -- ALPHA-STAR on Track for Initial Proof-of-Concept Results Anticipated Mid-2024 -- -- Mechanistic... | May 11, 2023

-- FDA Cleared IND Application for STAR-0215 for the Treatment of Hereditary Angioedema ---- Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects Initiated, Preliminary Results Anticipated by Year-End 2022 ---- Company to Host a Virtual R&D Day on September 30 --BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc....

-- On Track to File IND Application for STAR-0215 Mid-Year ---- Initial Phase 1a Clinical Results Anticipated by Year End 2022 --BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies fo...